Chronic obstructive pulmonary disease (COPD) is a significant contributor to the global disease burden. A systematic review aimed to evaluate the disease burden of chronic obstructive pulmonary disease in the Chinese population has been conducted. The review also sought to identify the factors that influence the economic burden of the disease.
A comprehensive search of various databases including PubMed, Web of Science, Embase, Chinese National Knowledge Infrastructure, WANGFANG Data, and VIP databases was carried out. The search included studies published before 31 December 2022, focusing on the disease burden of chronic obstructive pulmonary disease in mainland China. The risk of bias for cross-sectional studies was assessed using the Agency for Healthcare Research and Quality’s recommendation rating tool.
Chronic Obstructive Pulmonary Disease Burden and Economic Impact in China Over 30 Years
The systematic review included a total of 45 studies. The findings indicate that the disability-adjusted life years (DALYs) due to COPD have generally decreased in the Chinese population over the past 30 years. The total number of DALYs due to COPD in China reduced from 26.12 million person-years to 19.92 million person-years, indicating an annual decline rate of 0.9%.
The review also revealed that COPD is more prevalent among individuals aged 40 years and older, males, those living in rural areas, and in the West of China. The median direct medical cost of COPD was found to range from 150 to 2014 USD per capita per year. Among 23 influencing factors, age, hospitalization days, hospital type, gender, and career were identified as the most significant variables impacting the economic burden of COPD.
Despite the decreasing overall burden of COPD in China over the past 30 years, the review highlights a lack of standardized indicators for the economic burden of COPD patients in China. It is recommended to establish a unified standard for better assessment and management. The systematic review protocol was prospectively registered with PROSPERO.
Original Article DOI: 10.1177/17534666231218899
Original title: Disease burden of COPD in the Chinese population: a systematic review
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
